JO3669B1 - بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين - Google Patents

بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين

Info

Publication number
JO3669B1
JO3669B1 JOP/2016/0002A JOP20160002A JO3669B1 JO 3669 B1 JO3669 B1 JO 3669B1 JO P20160002 A JOP20160002 A JO P20160002A JO 3669 B1 JO3669 B1 JO 3669B1
Authority
JO
Jordan
Prior art keywords
cgrp antagonist
antagonist peptides
compounds
formula
peptides
Prior art date
Application number
JOP/2016/0002A
Other languages
English (en)
Inventor
J Sueiras-Diaz Javier
Jiang Guangcheng
K Rabinovich Aleksandr
Wisniewski Kazimierz
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JO3669B1 publication Critical patent/JO3669B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

-<span dir="RTL">يتعلق الإفصاح بمركبات من الصيغة (</span>I<span dir="RTL">) أو ملح منه مقبول دوائيا التي فيه </span>m<span dir="RTL"> و </span>p<span dir="RTL"> و </span>A<span dir="RTL"> و </span>Ar1<span dir="RTL"> و </span>Ar2<span dir="RTL"> و </span>Ar3<span dir="RTL"> و </span>R1<span dir="RTL"> و </span>R3<span dir="RTL"> و يتم تحديده في الوصف. يمكن أن تستخدم المركبات من الصيغة (</span>I<span dir="RTL">) حيث يمكن استخدام مثبطات الببتيد المرتبط بجين الكالسيتونين لعلاج الصداع النصفي.</span>
JOP/2016/0002A 2015-01-06 2016-01-04 بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين JO3669B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562100371P 2015-01-06 2015-01-06

Publications (1)

Publication Number Publication Date
JO3669B1 true JO3669B1 (ar) 2020-08-27

Family

ID=55071041

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0002A JO3669B1 (ar) 2015-01-06 2016-01-04 بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين

Country Status (34)

Country Link
US (1) US9969775B2 (ar)
EP (1) EP3242882B1 (ar)
JP (1) JP6929227B2 (ar)
KR (1) KR20170102302A (ar)
CN (1) CN107207567B (ar)
AR (1) AR103499A1 (ar)
AU (1) AU2016206059B2 (ar)
BR (1) BR112017013413A2 (ar)
CA (1) CA2973041A1 (ar)
CL (1) CL2017001761A1 (ar)
CO (1) CO2017007940A2 (ar)
DK (1) DK3242882T3 (ar)
EA (1) EA032082B1 (ar)
ES (1) ES2924410T3 (ar)
HR (1) HRP20220941T1 (ar)
HU (1) HUE059379T2 (ar)
IL (1) IL252903B (ar)
JO (1) JO3669B1 (ar)
LT (1) LT3242882T (ar)
MA (1) MA41311B1 (ar)
MD (1) MD3242882T2 (ar)
MX (1) MX2017008893A (ar)
MY (1) MY196439A (ar)
PH (1) PH12017501214A1 (ar)
PL (1) PL3242882T3 (ar)
PT (1) PT3242882T (ar)
RS (1) RS63467B1 (ar)
SA (1) SA517381865B1 (ar)
SG (1) SG11201705306UA (ar)
SI (1) SI3242882T1 (ar)
TN (1) TN2017000248A1 (ar)
TW (1) TWI717331B (ar)
UA (1) UA121490C2 (ar)
WO (1) WO2016110499A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019087161A1 (en) * 2017-11-06 2019-05-09 Auckland Uniservices Limited Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268474B1 (en) * 1998-04-30 2001-07-31 Creighton University Peptide antagonists of CGRP-receptor superfamily and methods of use
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
AU2005294448B2 (en) * 2004-10-07 2011-07-14 Merck Sharp & Dohme Corp. CGRP receptor antagonists
WO2006074964A1 (en) * 2005-01-17 2006-07-20 Jerini Ag C5a receptor antagonists
CA2599925A1 (en) * 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
AP2008004467A0 (en) * 2005-11-14 2008-06-30 Rinat Neurosciene Corp Antagonist antibodies directed against calcitonin generelated peptide anf methods using same
TW200813019A (en) * 2006-06-13 2008-03-16 Vertex Pharma CGRP receptor antagonists
ES2641325T3 (es) * 2012-01-26 2017-11-08 Christopher J. Soares Antagonistas peptídicos de la familia calcitonina CGRP de hormonas peptídicas y su uso

Also Published As

Publication number Publication date
MX2017008893A (es) 2017-10-25
AU2016206059B2 (en) 2019-07-25
KR20170102302A (ko) 2017-09-08
HRP20220941T1 (hr) 2022-10-28
PL3242882T3 (pl) 2022-10-31
PT3242882T (pt) 2022-08-09
EP3242882A1 (en) 2017-11-15
PH12017501214A1 (en) 2018-01-08
MA41311B1 (fr) 2022-10-31
WO2016110499A1 (en) 2016-07-14
TWI717331B (zh) 2021-02-01
MD3242882T2 (ro) 2022-10-31
CN107207567A (zh) 2017-09-26
EP3242882B1 (en) 2022-05-04
SA517381865B1 (ar) 2021-09-15
DK3242882T3 (en) 2022-08-08
SI3242882T1 (sl) 2022-09-30
EA201791456A1 (ru) 2018-01-31
JP2018505213A (ja) 2018-02-22
US9969775B2 (en) 2018-05-15
IL252903A0 (en) 2017-08-31
SG11201705306UA (en) 2017-07-28
LT3242882T (lt) 2022-08-25
ES2924410T3 (es) 2022-10-06
MA41311A (fr) 2017-11-14
JP6929227B2 (ja) 2021-09-01
BR112017013413A2 (pt) 2018-01-09
CN107207567B (zh) 2021-11-23
US20180002378A1 (en) 2018-01-04
CL2017001761A1 (es) 2018-01-26
IL252903B (en) 2021-01-31
CA2973041A1 (en) 2016-07-14
TW201630929A (zh) 2016-09-01
AR103499A1 (es) 2017-05-17
TN2017000248A1 (en) 2018-10-19
AU2016206059A1 (en) 2017-07-20
RS63467B1 (sr) 2022-08-31
UA121490C2 (uk) 2020-06-10
EA032082B1 (ru) 2019-04-30
HUE059379T2 (hu) 2022-11-28
CO2017007940A2 (es) 2017-10-31
MY196439A (en) 2023-04-11

Similar Documents

Publication Publication Date Title
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
PH12017502107A1 (en) Triazole agonists of the apj receptor
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
EA201591420A1 (ru) Гетероарильные соединения и их применение
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CL2015002897A1 (es) Inhibidores de bace1
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
EA201692289A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
NZ725165A (en) Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors
NZ738990A (en) Cgrp receptor antagonists
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
CL2016003102A1 (es) 1h-1,8-naftiridin-2-onas como compuestos antiproliferativos.
PH12017501214A1 (en) Cgrp antagonist peptides
AR101109A1 (es) Forma polimórfica del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina